Synthesis of Cyclopentane Monomers, SAMT-247, and Preclinical Studies

The National Institutes of Health (NIH) intends to award a contract to Frontage Laboratories, Inc. for the synthesis of cyclopentane monomers, SAMT-247, and preclinical studies. The contract is for the development of molecules with potential anti-cancer and anti-HIV activity. The scope of work includes the synthesis and evaluation of optimized molecules. • The contract is a non-competitive sole source award • The contract is for the development of molecules for the prevention and treatment of HIV infection • The contract includes preclinical studies • The contract is funded by the NIH Office of AIDS Research • The contract requires the contractor to have an active registration in the System for Award Management (SAM)